Sevasemten is a small molecule commercialized by Edgewise Therapeutics, with a leading Phase III program in Becker Muscular Dystrophy. According to Globaldata, it is involved in 12 clinical trials, of which 5 were completed, 6 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Sevasemten’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sevasemten is expected to reach an annual total of $478 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sevasemten (EDG-5506) is under development for the treatment of Duchenne muscular dystrophy, Becker muscular dystrophy, Limb girdle muscular dystrophy (LGMD), myocardial fibrosis and McArdle disease. It is administered through oral route. it acts by targeting myosin ATPase.
Edgewise Therapeutics Overview
Edgewise Therapeutics carries out the discovery, development and commercialization of innovative products to treat severe and rare muscle disorders. The company’s product portfolio includes EDG-5506, EDG-5440 and EDG-002. Its products are used in various therapeutic areas such as duchenne, limb-girdle and becker muscular dystrophy, hypertrophic cardiomyopathy, McArdle disease (also known as Glycogen storage disease type V or GSDV) and rare neuromuscular disease. Edgewise Therapeutics collaborates with a network of experts who advise and support its development activities. The company utilizes translatable systems to identify small-molecule precision medicines which regulate key proteins in muscle tissue. Edgewise Therapeutics is headquartered in Boulder, Colorado, the US.
The operating loss of the company was US$71.7 million in FY2022, compared to an operating loss of US$43.2 million in FY2021. The net loss of the company was US$67.6 million in FY2022, compared to a net loss of US$42.8 million in FY2021.
For a complete picture of Sevasemten’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.